Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 16/20 | 0.46 |
| ▸ | HTR2B | P41595 | 16/20 | 0.46 |
| ▸ | HTR2A | P28223 | 15/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966514 | 1.00 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL29966331 | 1.00 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30747194 | 0.91 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30069799 | 0.91 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL32664871 | 0.87 | PARP1 (0.41) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL29975791 | 0.87 | ESR1 (0.41) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30002807 | 0.86 | PARP1 (0.44) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30702593 | 0.86 | PARP1 (0.44) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30351677 | 0.85 | PARP1 (0.43) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30801290 | 0.85 | PARP1 (0.40) | PARP1HTR2CHTR2BHTR2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4565585-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023212599-A2 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ENDOTARGET INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2022237904-A1 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-11-17 | — | — | WO | disclosed |